Heritage Financial Services LLC Sells 185 Shares of Abbott Laboratories $ABT

Heritage Financial Services LLC reduced its position in Abbott Laboratories (NYSE:ABT) by 4.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,756 shares of the healthcare product maker’s stock after selling 185 shares during the period. Heritage Financial Services LLC’s holdings in Abbott Laboratories were worth $511,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Madrona Financial Services LLC boosted its stake in Abbott Laboratories by 9.7% in the second quarter. Madrona Financial Services LLC now owns 1,726 shares of the healthcare product maker’s stock valued at $235,000 after acquiring an additional 152 shares in the last quarter. SOA Wealth Advisors LLC. boosted its position in shares of Abbott Laboratories by 142.5% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 1,113 shares of the healthcare product maker’s stock worth $151,000 after purchasing an additional 654 shares in the last quarter. Parkwoods Wealth Partners LLC purchased a new position in Abbott Laboratories during the 2nd quarter worth $208,000. First Pacific Financial increased its position in Abbott Laboratories by 1,167.6% during the 2nd quarter. First Pacific Financial now owns 862 shares of the healthcare product maker’s stock valued at $117,000 after buying an additional 794 shares in the last quarter. Finally, Trilogy Capital Inc. boosted its holdings in Abbott Laboratories by 94.9% in the second quarter. Trilogy Capital Inc. now owns 4,849 shares of the healthcare product maker’s stock worth $660,000 after acquiring an additional 2,361 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. BTIG Research cut their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, July 18th. The Goldman Sachs Group upped their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Evercore ISI upped their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. Finally, Leerink Partners began coverage on Abbott Laboratories in a research report on Monday, June 16th. They set a “market perform” rating and a $143.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $145.39.

Abbott Laboratories Stock Down 0.3%

Abbott Laboratories stock opened at $133.53 on Thursday. The business’s 50-day moving average price is $131.63 and its 200 day moving average price is $131.24. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The firm has a market cap of $232.39 billion, a price-to-earnings ratio of 16.73, a price-to-earnings-growth ratio of 2.54 and a beta of 0.69. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s payout ratio is 29.57%.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.46% of the stock is currently owned by insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.